Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Zimmer Biomet Holdings' updated fair value estimate edges to US$102.95 from US$103.05, a change of less than 0.2%, giving you a fresh reference point for where some models currently anchor the stock. The slight adjustment sits alongside mixed Street commentary, with some analysts raising targets and others trimming them as they reassess execution risks and what rating makes sense. Read on to see how these moving pieces fit together so you can follow the evolving narrative around Zimmer Biomet with more context.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
TD Cowen assumed coverage with a Buy rating, signaling confidence in Zimmer Biomet's setup at current levels and seeing room for upside if management delivers on its plans.
-
UBS and Citi both raised their price targets in February 2026, underscoring interest in the risk or reward profile even as assumptions are being recalibrated.
-
William Blair's Market Perform initiation highlights that, in the firm's view, Zimmer Biomet has already "de risked" 2026 estimates by accounting for potential disruption, which some investors may read as a more balanced earnings setup.
🐻 Bearish Takeaways
-
BTIG's downgrade in March 2026 shows that not all firms are aligned, with the move reflecting concerns around execution and how that could affect the share's appeal.
-
UBS also lowered its price target in late January 2026, pointing to more cautious assumptions around the stock's upside relative to prior expectations.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for Zimmer Biomet Holdings. See which could impact your investment.
How This Changes the Fair Value For Zimmer Biomet Holdings
-
Fair value estimate adjusts to US$102.95 from US$103.05, a change of less than 0.2%.
-
Revenue growth assumption is updated to 3.75% from 3.65%.
-
Net profit margin assumption is set at 13.09% compared with 12.71% previously.
-
Future P/E multiple in the model is 20.83x, reduced from 21.52x.
-
Discount rate used in the model is 8.81% compared with 8.78% before.
Never Miss an Update: Follow The Narrative
Narratives connect Zimmer Biomet Holdings' business story to analyst forecasts and a fair value framework, so you can see what assumptions sit behind the numbers. They refresh as new data, news, and estimates come through, keeping the thesis current.
Head over to the Simply Wall St Community and follow the Narrative on Zimmer Biomet Holdings to stay up to date on:
-
How an aging population, higher procedure volumes, and joint replacement demand tie into Zimmer Biomet's core orthopedic franchise.
-
The role of digital health, robotics platforms such as ROSA and Monogram, and share repurchases in the current growth and margin story.
-
Key risks around pricing pressure, competition in robotics and orthopedics, acquisition integration, regulatory timelines, and global tariffs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ZBH .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
